<DOC>
	<DOCNO>NCT00898183</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue blood patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict patient respond treatment . PURPOSE : This laboratory study assess gene immune response tumor sample patient locally advance metastatic melanoma .</brief_summary>
	<brief_title>S9431 : Studying Genes Immune Response Tumor Samples From Patients With Locally Advanced Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Characterize frequency non-random cytogenetic abnormality regional distant melanoma metastasis explore association clinical outcome patient metastatic melanoma . - Characterize frequency specific genetic alteration either DNA , mRNA , protein level explore association abnormalities clinical outcome patient . - Characterize host immunologic response metastatic melanoma determine whether vivo pattern cytokine expression consistent specific subset T helper cell within melanoma deposit explore whether host immunologic response varies base site metastatic disease and/or correlate clinical outcome patient . - Obtain peripheral blood , serum , paraffin embed tumor block patient . - Correlate prevalent gene copy alteration observe metastatic disease risk progression tissue sample patient register SWOG-9035 ( primary melanoma ) . OUTLINE : Fresh snap frozen tumor tissue sample obtain biopsy surgical procedure coordinate study . Specimens undergo mRNA DNA analysis tumor-related gene cytokine gene expression . Peripheral blood sample obtain process serum mononuclear cell test . Tumor tissue sample embed paraffin unstained slide also obtain . PROJECTED ACCRUAL : Approximately 120 patient accrue study within 3-4 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis stage III IV metastatic melanoma Concurrent enrollment SWOGcoordinated melanoma treatment study ( within 56 day registration study ) OR Previously enrol eligible least 1 SWOGcoordinated melanoma study schedule undergo biopsy/surgery regional lymph node disseminate metastatic disease OR Concurrent enrollment SWOG9430 ( FISH analysis ) PATIENT CHARACTERISTICS : Age Not specify Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other Not previously enrol SWOG9431</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>